Epitope-specific tolerance induction with an engineered immunoglobulin

Elias Zambidis, D. W. Scott

Research output: Contribution to journalArticle

Abstract

Isologous and heterologous immunoglobulins have been shown to be extremely effective as tolerogenic carriers for nearly 30 years. The efficacy of these proteins is due in part to their long half-life in vivo, as well as their ability to crosslink surface IgM with Fc receptors. The concept of using IgG as a carrier molecule to induce unresponsiveness in the adult immune system has been exploited for simple haptens, such as nucleosides, as well as for peptides. To further evaluate the in vivo potential of these molecules for inducing tolerance to a defined epitope, we have engineered a fusion protein of mouse IgG1 with the immunodominant epitope 12-26 from bacteriophage λ cI repressor protein. This 15-mer, which contains both a B-cell and T-cell epitope, has been fused in-frame to the N terminus of a mouse heavy chain IgG1 construct, thus creating a 'genetic hapten-carrier' system. We describe a novel in vitro and in vivo experimental system for studying the feasibility of engineered tolerogens, consisting of a recombinant flagellin challenge antigen and a murine IgG1 tolerogen, both expressing the λ repressor epitope 12-26. Herein, we show that peptide-grafted IgG molecules injected i.v., or expressed by transfected, autologous B cells, can efficiently modulate the cellular and humoral immune responses to immunodominant epitopes. This model displays the feasibility of 'tailor-designing' immune responses to whole antigens by selecting epitopes for either tolerance or immunity.

Original languageEnglish (US)
Pages (from-to)5019-5024
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume93
Issue number10
DOIs
StatePublished - May 14 1996
Externally publishedYes

Fingerprint

Immunoglobulins
Epitopes
Immunoglobulin G
Immunodominant Epitopes
Haptens
B-Lymphocytes
Repressor Proteins
Flagellin
Antigens
Peptides
T-Lymphocyte Epitopes
Heterozygote
Humoral Immunity
Nucleosides
Cellular Immunity
Bacteriophages
Half-Life
Immune System
Immunity
Proteins

Keywords

  • antigen presentation
  • gene therapy
  • immune self-tolerance
  • protein engineering

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Epitope-specific tolerance induction with an engineered immunoglobulin. / Zambidis, Elias; Scott, D. W.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, No. 10, 14.05.1996, p. 5019-5024.

Research output: Contribution to journalArticle

@article{f375d7b449134c8aa0ba8ee469ea1bef,
title = "Epitope-specific tolerance induction with an engineered immunoglobulin",
abstract = "Isologous and heterologous immunoglobulins have been shown to be extremely effective as tolerogenic carriers for nearly 30 years. The efficacy of these proteins is due in part to their long half-life in vivo, as well as their ability to crosslink surface IgM with Fc receptors. The concept of using IgG as a carrier molecule to induce unresponsiveness in the adult immune system has been exploited for simple haptens, such as nucleosides, as well as for peptides. To further evaluate the in vivo potential of these molecules for inducing tolerance to a defined epitope, we have engineered a fusion protein of mouse IgG1 with the immunodominant epitope 12-26 from bacteriophage λ cI repressor protein. This 15-mer, which contains both a B-cell and T-cell epitope, has been fused in-frame to the N terminus of a mouse heavy chain IgG1 construct, thus creating a 'genetic hapten-carrier' system. We describe a novel in vitro and in vivo experimental system for studying the feasibility of engineered tolerogens, consisting of a recombinant flagellin challenge antigen and a murine IgG1 tolerogen, both expressing the λ repressor epitope 12-26. Herein, we show that peptide-grafted IgG molecules injected i.v., or expressed by transfected, autologous B cells, can efficiently modulate the cellular and humoral immune responses to immunodominant epitopes. This model displays the feasibility of 'tailor-designing' immune responses to whole antigens by selecting epitopes for either tolerance or immunity.",
keywords = "antigen presentation, gene therapy, immune self-tolerance, protein engineering",
author = "Elias Zambidis and Scott, {D. W.}",
year = "1996",
month = "5",
day = "14",
doi = "10.1073/pnas.93.10.5019",
language = "English (US)",
volume = "93",
pages = "5019--5024",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "10",

}

TY - JOUR

T1 - Epitope-specific tolerance induction with an engineered immunoglobulin

AU - Zambidis, Elias

AU - Scott, D. W.

PY - 1996/5/14

Y1 - 1996/5/14

N2 - Isologous and heterologous immunoglobulins have been shown to be extremely effective as tolerogenic carriers for nearly 30 years. The efficacy of these proteins is due in part to their long half-life in vivo, as well as their ability to crosslink surface IgM with Fc receptors. The concept of using IgG as a carrier molecule to induce unresponsiveness in the adult immune system has been exploited for simple haptens, such as nucleosides, as well as for peptides. To further evaluate the in vivo potential of these molecules for inducing tolerance to a defined epitope, we have engineered a fusion protein of mouse IgG1 with the immunodominant epitope 12-26 from bacteriophage λ cI repressor protein. This 15-mer, which contains both a B-cell and T-cell epitope, has been fused in-frame to the N terminus of a mouse heavy chain IgG1 construct, thus creating a 'genetic hapten-carrier' system. We describe a novel in vitro and in vivo experimental system for studying the feasibility of engineered tolerogens, consisting of a recombinant flagellin challenge antigen and a murine IgG1 tolerogen, both expressing the λ repressor epitope 12-26. Herein, we show that peptide-grafted IgG molecules injected i.v., or expressed by transfected, autologous B cells, can efficiently modulate the cellular and humoral immune responses to immunodominant epitopes. This model displays the feasibility of 'tailor-designing' immune responses to whole antigens by selecting epitopes for either tolerance or immunity.

AB - Isologous and heterologous immunoglobulins have been shown to be extremely effective as tolerogenic carriers for nearly 30 years. The efficacy of these proteins is due in part to their long half-life in vivo, as well as their ability to crosslink surface IgM with Fc receptors. The concept of using IgG as a carrier molecule to induce unresponsiveness in the adult immune system has been exploited for simple haptens, such as nucleosides, as well as for peptides. To further evaluate the in vivo potential of these molecules for inducing tolerance to a defined epitope, we have engineered a fusion protein of mouse IgG1 with the immunodominant epitope 12-26 from bacteriophage λ cI repressor protein. This 15-mer, which contains both a B-cell and T-cell epitope, has been fused in-frame to the N terminus of a mouse heavy chain IgG1 construct, thus creating a 'genetic hapten-carrier' system. We describe a novel in vitro and in vivo experimental system for studying the feasibility of engineered tolerogens, consisting of a recombinant flagellin challenge antigen and a murine IgG1 tolerogen, both expressing the λ repressor epitope 12-26. Herein, we show that peptide-grafted IgG molecules injected i.v., or expressed by transfected, autologous B cells, can efficiently modulate the cellular and humoral immune responses to immunodominant epitopes. This model displays the feasibility of 'tailor-designing' immune responses to whole antigens by selecting epitopes for either tolerance or immunity.

KW - antigen presentation

KW - gene therapy

KW - immune self-tolerance

KW - protein engineering

UR - http://www.scopus.com/inward/record.url?scp=0029995883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029995883&partnerID=8YFLogxK

U2 - 10.1073/pnas.93.10.5019

DO - 10.1073/pnas.93.10.5019

M3 - Article

C2 - 8643522

AN - SCOPUS:0029995883

VL - 93

SP - 5019

EP - 5024

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 10

ER -